Company Overview and News
Gold prices have fallen for the last six months on the trot, marking the longest streak of losses in nearly three decades. This is because rising rate concerns in the United States have given a boost to the greenback. Invesco DB US Dollar Bullish (UUP - Free Report) is up about 6.2% this year (as of Oct 9, 2018). Since gold prices act inversely to the U.S. dollar, gold bullion ETF SPDR Gold Shares (GLD - Free Report) has lost about 10% this year (as of Oct 9, 2018).
GLDM WFC WFCNP BAR GPL GLD IAU
2018-09-25 seekingalpha - 1
Another CEO is having a shot at fixing New Gold. Unfortunately, things have gone from bad to worse since the last iteration on this theme. Welcome to this week's
OCANF CAT IVN LIACF TMMFF NGD NSU BTR AMGGF IAG IPMLF ABX III NGD GPL OKSWF EQXGF RGLD ATUSF MNIKF AMLM OSKGF VTT RGL HRT VDTAF HRTFF BDREF CGOOF KGI.DB NGDAF CG VITFF TREVF AGI CAGDF OR RIC CSFFF CS KL CORVF EGO RIC ABX KOR KGI KGI.DB.A AGI BDR VIT IVPAF TMR ELD
2018-09-24 sec.gov - 1
Beadell Resources Ltd (ASX:BDR) has entered into a scheme implementation deed under which Great Panther Silver Ltd (TSE:GPR) (NYSE:GPL) will acquire all of Beadell’s issued ordinary shares.
GPL BDREF BDR
In case you missed out on previous editions of this newsletter, simply click here, here or here to catch up.
OCANF EMRRF LUNMF CNL MUN NSU FNLPF TGB THO MUX.RTWI MAG EVM MUNMF MUX SEMFF NEVDF ABX TAHO GPL MUX OKSWF CDEUW BGMZF DRGDF CDE LYDIF NCU OSKGF MAG APR APRLY TKO EXK NEM CPNFD CGOOF LUNCF GSV TECK DGC EDVVF OR TCKRF EDR GG EDV ABX EDVMF DPMLF LUN EVR
2018-09-05 sec.gov - 2
EDMONTON, Alberta, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Alcanna Inc. (the “Company” or “Alcanna”) (TSX: CLIQ) announced that Elise Rees, FCPA, FCA, ICD.D has joined its Board of Directors.
ACB GPL ACBFF
2018-08-02 seekingalpha - 1
Great Panther Silver Limited (NYSEMKT:GPL) Q2 2018 Earnings Conference Call August 2, 2018 11:00 AM ET
2018-08-02 seekingalpha - 4
The following slide deck was published by Great Panther Silver Limited in conjunction with their 2018 Q2 earnings call.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET